Apoptotic cell signaling in cancer progression and therapy.

Apoptosis is a tightly regulated cell suicide program that plays an essential role in the development and maintenance of tissue homeostasis by eliminating unnecessary or harmful cells. Impairment of this native defense mechanism promotes aberrant cellular proliferation and the accumulation of genetic defects, ultimately resulting in tumorigenesis, and frequently confers drug resistance to cancer cells. The regulation of apoptosis at several levels is essential to maintain the delicate balance between cellular survival and death signaling that is required to prevent disease. Complex networks of signaling pathways act to promote or inhibit apoptosis in response to various cues. Apoptosis can be triggered by signals from within the cell, such as genotoxic stress, or by extrinsic signals, such as the binding of ligands to cell surface death receptors. Various upstream signaling pathways can modulate apoptosis by converging on, and thereby altering the activity of, common central control points within the apoptotic signaling pathways, which involve the BCL-2 family proteins, inhibitor of apoptosis (IAP) proteins, and FLICE-inhibitory protein (c-FLIP). This review highlights the role of these fundamental regulators of apoptosis in the context of both normal apoptotic signaling mechanisms and dysregulated apoptotic pathways that can render cancer cells resistant to cell death. In addition, therapeutic strategies aimed at modulating the activity of BCL-2 family proteins, IAPs, and c-FLIP for the targeted induction of apoptosis are briefly discussed.

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  C. Croce,et al.  microRNAs: Master regulators as potential therapeutics in cancer. , 2011, Annual review of pharmacology and toxicology.

[3]  J. Martinez-Climent,et al.  Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. , 2010, Blood.

[4]  D. Altieri Survivin and IAP proteins in cell-death mechanisms. , 2010, The Biochemical journal.

[5]  H. Kashkar X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise , 2010, Clinical Cancer Research.

[6]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[7]  C. Pepper,et al.  The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. , 2010, Leukemia research.

[8]  C. Boland,et al.  Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability , 2010, BMC Cancer.

[9]  Mallika Singh,et al.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models , 2010, Nature Biotechnology.

[10]  Subbaya Subramanian,et al.  MicroRNAs as gatekeepers of apoptosis , 2010, Journal of cellular physiology.

[11]  C. Croce,et al.  MicroRNAs as regulators of death receptors signaling , 2010, Cell Death and Differentiation.

[12]  J. Houghton,et al.  Inhibition of NF-κB Signaling by Quinacrine Is Cytotoxic to Human Colon Carcinoma Cell Lines and Is Synergistic in Combination with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) or Oxaliplatin , 2010, The Journal of Biological Chemistry.

[13]  C. Meijer,et al.  Molecular targeted therapies for diffuse large B‐cell lymphoma based on apoptosis profiles , 2010, The Journal of pathology.

[14]  M. Baker RNA interference: Homing in on delivery , 2010, Nature.

[15]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[16]  Jian Yu,et al.  Mitochondrial signaling in cell death via the Bcl-2 family , 2010, Cancer biology & therapy.

[17]  Raimund Mannhold,et al.  IAP antagonists: promising candidates for cancer therapy. , 2010, Drug discovery today.

[18]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[19]  S. Fulda Evasion of Apoptosis as a Cellular Stress Response in Cancer , 2010, International journal of cell biology.

[20]  G. Brumatti,et al.  Crossing paths: interactions between the cell death machinery and growth factor survival signals , 2010, Cellular and Molecular Life Sciences.

[21]  D. Green,et al.  The BCL-2 family reunion. , 2010, Molecular cell.

[22]  L. Blum,et al.  Active Fragments from Pro- and Antiapoptotic BCL-2 Proteins Have Distinct Membrane Behavior Reflecting Their Functional Divergence , 2010, PloS one.

[23]  C. Croce,et al.  miR-15a and miR-16-1 in cancer: discovery, function and future perspectives , 2010, Cell Death and Differentiation.

[24]  S. Canevari,et al.  Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. , 2010, The international journal of biochemistry & cell biology.

[25]  H. Hermeking The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[26]  W. Fairbrother,et al.  Small-molecule pan-IAP antagonists: a patent review , 2010, Expert opinion on therapeutic patents.

[27]  L. Languino,et al.  IAP regulation of metastasis. , 2010, Cancer cell.

[28]  C. Croce,et al.  MicroRNA 29b functions in acute myeloid leukemia. , 2009, Blood.

[29]  Liu Hao,et al.  Expression of X‐linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis , 2009, Journal of surgical oncology.

[30]  H. Steinhoff,et al.  Molecular Details of Bax Activation, Oligomerization, and Membrane Insertion* , 2009, The Journal of Biological Chemistry.

[31]  P. Meier,et al.  A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. , 2009, Molecular cell.

[32]  J. Hsieh,et al.  Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. , 2009, Molecular cell.

[33]  S. Bruno,et al.  BH3‐only proteins: The death‐puppeteer's wires , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[34]  T. Hofmann,et al.  Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling – roles of p53, p73 and HIPK2 , 2009, The FEBS journal.

[35]  M. Duffy,et al.  Survivin: a new target for anti-cancer therapy. , 2009, Cancer treatment reviews.

[36]  A. Chanan-Khan,et al.  Targeting the Bcl-2 , 2009, Current opinion in oncology.

[37]  J. Yun,et al.  Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma , 2009, Hepatology.

[38]  C. Croce Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[39]  M. Kurokawa,et al.  Caspases and Kinases in a Death Grip , 2009, Cell.

[40]  Min Zhang,et al.  MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.

[41]  S. Fulda Caspase-8 in cancer biology and therapy. , 2009, Cancer letters.

[42]  G. Dewson,et al.  Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis , 2009, Journal of Cell Science.

[43]  Erinna F. Lee,et al.  The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins , 2009, The Journal of cell biology.

[44]  M. Willingham,et al.  Expression of the Bcl-2 Protein BAD Promotes Prostate Cancer Growth , 2009, PloS one.

[45]  T. Cotter,et al.  Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.

[46]  M. Aung,et al.  Role of the miR‐106b‐25 microRNA cluster in hepatocellular carcinoma , 2009, Cancer science.

[47]  T. Wilson,et al.  Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing , 2009, Cell Death and Differentiation.

[48]  B. Cravatt,et al.  Comparative assessment of large-scale proteomic studies of apoptotic proteolysis. , 2009, ACS chemical biology.

[49]  D. Saur,et al.  HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.

[50]  W. Filipowicz,et al.  Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. , 2009, Current opinion in cell biology.

[51]  G. Gores,et al.  Life and death by death receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  A. Safa,et al.  RNA interference in cancer: targeting the anti-apoptotic protein c-FLIP for drug discovery. , 2009, Mini reviews in medicinal chemistry.

[53]  G. Salvesen,et al.  Human Caspases: Activation, Specificity, and Regulation* , 2009, The Journal of Biological Chemistry.

[54]  Yigong Shi,et al.  Mechanism of procaspase-8 activation by c-FLIPL , 2009, Proceedings of the National Academy of Sciences.

[55]  F. Sato,et al.  The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. , 2009, Gastroenterology.

[56]  S. de Jong,et al.  TRAIL receptor signalling and modulation: Are we on the right TRAIL? , 2009, Cancer treatment reviews.

[57]  T. Wilson,et al.  Anti-apoptotic mechanisms of drug resistance in cancer. , 2009, Current cancer drug targets.

[58]  P. Gimenez-Bonafe,et al.  Overcoming drug resistance by enhancing apoptosis of tumor cells. , 2009, Current cancer drug targets.

[59]  D. Green,et al.  Cytoplasmic functions of the tumour suppressor p53 , 2009, Nature.

[60]  G. Torzilli,et al.  Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma , 2009, BMC Cancer.

[61]  J. Hickman,et al.  Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members , 2009, The Journal of cell biology.

[62]  A. Letai Puma strikes Bax , 2009, The Journal of cell biology.

[63]  Mark E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[64]  L. Donehower,et al.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. , 2009, Cancer research.

[65]  S. Fulda Inhibitor of apoptosis proteins in hematological malignancies , 2009, Leukemia.

[66]  G. Bao,et al.  Expression and biological significance of c-FLIP in human hepatocellular carcinomas , 2009, Journal of experimental & clinical cancer research : CR.

[67]  C. Reynolds,et al.  Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.

[68]  A. Letai,et al.  Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.

[69]  S. Fulda Tumor resistance to apoptosis , 2009, International journal of cancer.

[70]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[71]  D. Andrews,et al.  Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax , 2008, Cell.

[72]  P. Bouillet,et al.  BH3-only proteins and their roles in programmed cell death , 2008, Oncogene.

[73]  D. Andrews,et al.  Bid: a Bax-like BH3 protein , 2008, Oncogene.

[74]  C. Scott,et al.  In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas , 2008, Proceedings of the National Academy of Sciences.

[75]  Hiroyuki Tagawa,et al.  MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. , 2008, Blood.

[76]  V. Duronio The life of a cell: apoptosis regulation by the PI3K/PKB pathway. , 2008, The Biochemical journal.

[77]  R. Hofer-Warbinek,et al.  XIAP regulates bi-phasic NF-kappaB induction involving physical interaction and ubiquitination of MEKK2. , 2008, Cellular signalling.

[78]  John Calvin Reed,et al.  Bcl-2 family proteins and cancer , 2008, Oncogene.

[79]  Junying Yuan,et al.  Caspases in apoptosis and beyond , 2008, Oncogene.

[80]  S. Baird,et al.  IAP-targeted therapies for cancer , 2008, Oncogene.

[81]  Yigong Shi,et al.  FLIP and the death effector domain family , 2008, Oncogene.

[82]  Min Zhang,et al.  Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres , 2008, BMC Cancer.

[83]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[84]  K. Pienta,et al.  Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa , 2008, Molecular Cancer Therapeutics.

[85]  R. Khosravi‐Far,et al.  Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities , 2008, Journal of cellular biochemistry.

[86]  D. Andrews,et al.  Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax , 2008, PLoS biology.

[87]  Simone Fulda,et al.  Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.

[88]  A. Donfrancesco,et al.  Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM , 2008, PloS one.

[89]  Xiaodong Wang,et al.  TNF-α Induces Two Distinct Caspase-8 Activation Pathways , 2008, Cell.

[90]  P. Colman,et al.  To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. , 2008, Molecular cell.

[91]  F. Kruyt TRAIL and cancer therapy. , 2008, Cancer letters.

[92]  Sharon J. Diskin,et al.  A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.

[93]  D. Radisky,et al.  Mechanisms of Disease: epithelial–mesenchymal transition—does cellular plasticity fuel neoplastic progression? , 2008, Nature Clinical Practice Oncology.

[94]  John Calvin Reed Bcl-2-family proteins and hematologic malignancies: history and future prospects. , 2008, Blood.

[95]  C. Croce,et al.  MiR-15a and miR-16-1 cluster functions in human leukemia , 2008, Proceedings of the National Academy of Sciences.

[96]  H. Mertsching,et al.  Human skin equivalent as an alternative to animal testing , 2008, GMS Krankenhaushygiene interdisziplinar.

[97]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[98]  S. Ghosh,et al.  Shared Principles in NF-κB Signaling , 2008, Cell.

[99]  V. Bumbasirevic,et al.  TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2 , 2008, Cellular and Molecular Life Sciences.

[100]  V. Seifert,et al.  Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma , 2008, Journal of Neuro-Oncology.

[101]  A. Safa,et al.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. , 2008, Current cancer drug targets.

[102]  N. Danial,et al.  BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death , 2007, Clinical Cancer Research.

[103]  Xiao-yong Lei,et al.  Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. , 2007, Acta biochimica et biophysica Sinica.

[104]  B. Gillissen,et al.  Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance , 2007, Oncogene.

[105]  H. Otu,et al.  c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. , 2007, Cancer research.

[106]  G. Gores,et al.  mir-29 regulates Mcl-1 protein expression and apoptosis , 2007, Oncogene.

[107]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[108]  P. Korkolopoulou,et al.  c‐FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications , 2007, Histopathology.

[109]  F. Khuri,et al.  Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. , 2007, Cancer research.

[110]  D. Altieri,et al.  Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. , 2007, Molecular cell.

[111]  Xiao-yong Lei,et al.  Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells. , 2007, Acta biochimica et biophysica Sinica.

[112]  Dimitri Semizarov,et al.  Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains , 2007, Molecular Cancer Research.

[113]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[114]  David W. Andrews,et al.  Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes , 2007, Apoptosis.

[115]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[116]  S. Martin,et al.  The CASBAH: a searchable database of caspase substrates , 2007, Cell Death and Differentiation.

[117]  M. Bissell Modelling molecular mechanisms of breast cancer and invasion: lessons from the normal gland. , 2007, Biochemical Society transactions.

[118]  C. Castilla,et al.  Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. , 2006, Endocrinology.

[119]  Mallika Singh,et al.  Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective , 2006, Clinical Cancer Research.

[120]  G. Salvesen,et al.  Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family , 2006, EMBO reports.

[121]  Zhengxin Wang,et al.  Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. , 2006, Journal of molecular endocrinology.

[122]  B. Dörken,et al.  Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma , 2006, Cell Death and Differentiation.

[123]  G. Salvesen,et al.  The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases* , 2006, Journal of Biological Chemistry.

[124]  M. Reth,et al.  Human T‐cell leukemia virus type‐I oncoprotein Tax inhibits Fas‐mediated apoptosis by inducing cellular FLIP through activation of NF‐κB , 2006 .

[125]  M. Hinds,et al.  Regulation of apoptosis: uncovering the binding determinants. , 2005, Current opinion in structural biology.

[126]  Ki-Young Lee,et al.  TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. , 2005, Genes & development.

[127]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.

[128]  D. Newmeyer,et al.  Mitochondria: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.

[129]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[130]  M. Shipp,et al.  Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. , 2005, Blood.

[131]  Y-j Liu,et al.  Expression of cellular FLICE/caspase‐8 inhibitory protein is associated with malignant potential in endometrial carcinoma , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[132]  Jyotika Sharma,et al.  Bcl-XL Protein Levels Determine Apoptotic Index in Pancreatic Carcinoma , 2005, Pancreas.

[133]  P. Krammer,et al.  c-FLIPR, a New Regulator of Death Receptor-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[134]  J. Sabourin,et al.  Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. , 2005, American journal of clinical pathology.

[135]  W. Marasco,et al.  Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. , 2005, Cancer research.

[136]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[137]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[138]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[139]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[140]  W. El-Deiry,et al.  Overview of cell death signaling pathways , 2005, Cancer biology & therapy.

[141]  P. Isaacson,et al.  Gastrointestinal lymphoma: where morphology meets molecular biology , 2005, The Journal of pathology.

[142]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[143]  R. Khosravi‐Far Death receptor signals to the mitochondria , 2004, Cancer biology & therapy.

[144]  Hongmei Yang,et al.  Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate Cancer , 2004, Cancer Research.

[145]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[146]  Victor E. Marquez,et al.  Microarray Analysis of Epigenetic Silencing of Gene Expression in the KAS-6/1 Multiple Myeloma Cell Line , 2004, Cancer Research.

[147]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[148]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[149]  Wei-Guo Zhu,et al.  A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. , 2003, Human molecular genetics.

[150]  D. Green,et al.  A unified model for apical caspase activation. , 2003, Molecular cell.

[151]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[152]  S. Matsuda,et al.  Bcl-xL overexpression in human hepatocellular carcinoma. , 2002, International journal of oncology.

[153]  Sophie Lelièvre,et al.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. , 2002, Cancer cell.

[154]  Xiaolu Yang,et al.  c‐FLIPL is a dual function regulator for caspase‐8 activation and CD95‐mediated apoptosis , 2002, The EMBO journal.

[155]  G. Kroemer Introduction: mitochondrial control of apoptosis. , 2002, Biochimie.

[156]  X. Wang The expanding role of mitochondria in apoptosis. , 2001, Genes & development.

[157]  D. Crețoiu,et al.  Phagocytosis of apoptotic cells by microglia in vitro , 2001, Journal of cellular and molecular medicine.

[158]  J. Inazawa,et al.  Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. , 2001, Cancer research.

[159]  Peter Scheurich,et al.  NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling , 2001, Molecular and Cellular Biology.

[160]  M J Bissell,et al.  Tumors are unique organs defined by abnormal signaling and context. , 2001, Seminars in cancer biology.

[161]  R. Korneluk,et al.  Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. , 2000, Genomics.

[162]  Claus Belka,et al.  Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis , 2000, Oncogene.

[163]  R. Meyermann,et al.  Antiapoptotic Bcl‐2 family protein expression increases with progression of oligodendroglioma , 1999, Cancer.

[164]  V. Weaver,et al.  Functional Culture Models to Study Mechanisms Governing Apoptosis in Normal and Malignant Mammary Epithelial Cells , 1999, Journal of Mammary Gland Biology and Neoplasia.

[165]  Emad S. Alnemri,et al.  Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.

[166]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[167]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[168]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[169]  V. Weaver,et al.  Structural Cues from the Tissue Microenvironment Are Essential Determinants of the Human Mammary Epithelial Cell Phenotype , 1998, Journal of Mammary Gland Biology and Neoplasia.

[170]  John Calvin Reed,et al.  BCL-X expression in multiple myeloma: possible indicator of chemoresistance. , 1998, Cancer research.

[171]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[172]  K. Franssila,et al.  BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.

[173]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[174]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[175]  C. Thompson,et al.  Kaposi's sarcoma tumor cells preferentially express Bcl-xL. , 1996, The American journal of pathology.

[176]  L. Verburgt,et al.  Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. , 1996, American journal of respiratory cell and molecular biology.

[177]  John Calvin Reed,et al.  Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. , 1996, Cancer research.

[178]  Z. Werb,et al.  Extracellular matrix remodeling and the regulation of epithelial-stromal interactions during differentiation and involution. , 1996, Kidney international. Supplement.

[179]  M J Bissell,et al.  A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. , 1995, Current opinion in cell biology.

[180]  L. From,et al.  bcl-2 protein expression in melanocytic neoplasms of the skin. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[181]  J. Camonis,et al.  Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects (*) , 1995, The Journal of Biological Chemistry.

[182]  D. Chopin,et al.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. , 1993, The American journal of pathology.

[183]  F. Behm,et al.  Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. , 1993, Blood.

[184]  Y. Tsujimoto,et al.  Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.

[185]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[186]  C. Day,et al.  Assembling the building blocks: structure and function of inhibitor of apoptosis proteins , 2010, Cell Death and Differentiation.

[187]  C. Duckett,et al.  XIAP as a ubiquitin ligase in cellular signaling , 2010, Cell Death and Differentiation.

[188]  R. Agami,et al.  Tumorigenicity of the miR-17-92 cluster distilled. , 2010, Genes & development.

[189]  M. Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[190]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[191]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.

[192]  Sharad Kumar,et al.  Caspase function in programmed cell death , 2007, Cell Death and Differentiation.

[193]  A. Venditti,et al.  Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. , 2004, Haematologica.

[194]  H. Pehamberger,et al.  Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. , 2003, Oligonucleotides.

[195]  Wafik S El-Deiry,et al.  Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.

[196]  M J Bissell,et al.  The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.